The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Sanofi will acquire Vicebio for USD 1.15 bn, gaining RSV/hMPV vaccine candidates plus the Molecular Clamp platform for refrigeration‑stable combination vaccines. Deal expected by Q4 2025, supporting ...

Casper claimed that during the quarter, Thermo Fisher advanced its growth strategy, launching a range of high-impact ...

Sanofi (NASDAQ:SNY)’s vaccine is supplied as a ready-to-use liquid in single-dose vials, streamlining administration. This expansion comes amid a recent rise in U.S. meningococcal disease cases ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read more here.

French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company (VNVC), which ...